Renal Cancer

Time trend and age-period-cohort effect on kidney cancer mortality in spain, 1983-2022.

This study examines trends and disparities in kidney cancer (KC) mortality in Spain from 1983 to 2022, focusing on gender, birth cohort, and age influences.

Data from the Spanish National Institute of Statistics were analyzed using age-standardized mortality rates (ASMRs).

Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma.

Immunotherapies targeting PD-1 and CTLA-4 are key components of the treatment of metastatic clear cell renal cell carcinoma (mccRCC). However, they have distinct safety profiles and resistance to treatment can occur.

Characteristics of patients with metastatic renal cell carcinoma who do not respond to axitinib treatment.

Axitinib is a widely used tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma (mRCC) treatment. Here, we analyzed the characteristics of patients who did not respond to axitinib and evaluated alternative options for their treatment.

[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.

With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect clear-cell renal cell carcinoma in patients with renal masses remain an unmet need. 89Zr-labelled monoclonal antibody ([89Zr]Zr-girentuximab) has high affinity for carbonic anhydrase 9, a tumour antigen highly expressed in clear-cell renal cell carcinoma.

Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.

Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study was designed to determine the antitumour activity and safety of belzutifan in combination with cabozantinib in patients with advanced clear-cell renal cell carcinoma that was previously untreated (cohort 1) or previously treated with immunotherapy (cohort 2).

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.

Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL with checkpoint blockade may result in improved response to immunotherapy.

Pathogenicity of germline VHL variants is associated with renal cell carcinoma size in von Hippel-Lindau disease.

In this study, our aim was to search for new genotype-phenotype correlations in patients with Von Hippel-Lindau (VHL) disease.

We retrospectively studied 53 consecutive patients with VHL disease and confirmed genetic diagnoses from 32 relatives.

Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review.

metastasis-directed treatment (MDT) is progressively expanding its scope in the treatment of metastatic renal cell carcinoma (mRCC), finding application both in cases of oligometastatic disease, whether synchronous or metachronous, and in oligo-progression during systemic therapy (ST).

Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment.

To quantify patients' preferences for adjuvant renal cell carcinoma (RCC) treatments.

Preferences were elicited using a discrete-choice experiment requiring RCC patients to choose between 2 hypothetical treatments.

Organoids as Sophisticated Tools for Renal Cancer Research: Extensive Applications and Promising Prospects.

Kidney cancer is a significant global health problem that affects nearly 1 in 25 of cancer patients. Prevalence, morbidity and mortality data associated with kidney cancer continue to increase every year, revealing a heavy economic and social burden.